New immune combo shows promise for liver cancer control
NCT ID NCT02519348
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study tested two immune-boosting drugs, durvalumab and tremelimumab, given alone or together (sometimes with a third drug, bevacizumab) in 433 adults with advanced liver cancer. The goal was to see if these treatments are safe and can shrink or slow the cancer. Participants had already tried other treatments or could not take them. The study focused on controlling the disease, not curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Phoenix, Arizona, 85054, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
New Haven, Connecticut, 06510, United States
-
Research Site
Jacksonville, Florida, 32224, United States
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Indianapolis, Indiana, 46202, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Stony Brook, New York, 11794, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Philadelphia, Pennsylvania, 19107, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Dallas, Texas, 75390, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Hangzhou, 310016, China
-
Research Site
Nanjing, 210002, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Hong Kong, Hong Kong
-
Research Site
Shatin, Hong Kong
-
Research Site
Benevento, 82100, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Osakasayama-shi, 589-8511, Japan
-
Research Site
Bukit Merah, 169610, Singapore
-
Research Site
Singapore, 119074, Singapore
-
Research Site
Singapore, 308433, Singapore
-
Research Site
Busan, 49241, South Korea
-
Research Site
Junggu, 41944, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06273, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Kaohsiung City, 83301, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taoyuan City, 333, Taiwan
Conditions
Explore the condition pages connected to this study.